AstraZeneca Sets $35 Monthly Cap on Inhaler Costs
Starting June 1, eligible patients will pay no more than $35 per month for all AstraZeneca US inhaled respiratory medicines.
Starting June 1, eligible patients will pay no more than $35 per month for all AstraZeneca US inhaled respiratory medicines.
The FDA approved osimertinib (Tagrisso) with platinum-based chemotherapy for certain patients with non-small cell lung cancer (NSCLC).
Cedars-Sinai investigators suggest it may be helpful to keep an eye on patients with underlying health issues after COVID-19 vaccination to monitor for post-vaccine POTS, a condition that causes an abnormal increase in heart rate after standing or sitting up.
Combining immunotherapy with dupilumab boosted lung cancer patients’ immune systems, with one out of the six experiencing significant tumor reduction, according to findings published in Nature.
Read MoreIn an early parallel study in humans with non-small cell lung cancer, combining immunotherapy with dupilumab boosted patients’ immune systems, with one out of the six experiencing significant tumor reduction.
Read MoreAstraZeneca’s Imfinzi (durvalumab) concurrently administered with chemoradiotherapy did not achieve a Phase 3 primary endpoint of progression-free survival versus CRT alone for the treatment of patients with unresectable, Stage III non-small cell lung cancer.
Read MoreAn observational study found that patients treated with nirmatrelvir-ritonavir for acute COVID-19 showed more frequent virologic rebound compared to those not receiving the treatment.
Read MoreA new VA study finds a 45% reduction in Clostridioides difficile infections among high-risk patients with the use of doxycycline instead of azithromycin.
Read MoreThe FDA has become aware that some providers may not realize the Moderna COVID-19 vaccine vial for ages 6 months to 11 years holds more than the 0.25 mL dose.
Read MoreAileron Therapeutics acquired Lung Therapeutics Inc, a biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications.
Read MoreUTHealth Houston researchers were awarded a four-year, $3.4 million NIH grant to investigate molecular mechanisms and therapeutic treatments for acute respiratory distress syndrome.
Read MoreA trial emulation study of veterans with COVID-19 found that the use of the antiviral nirmatrelvir–ritonavir (Paxlovid) was not effective for reducing the risk for many post-COVID-19 conditions.
Read MoreA supplemental biologics application for AstraZeneca’s FluMist Quadrivalent is currently being reviewed by the FDA. If approved, FluMist would be the first needle-free, nasal spray influenza vaccine available to be self-administered by patients or caregivers.
Read MorePre- and post-surgical immunotherapy, combined with chemotherapy, improved survival rates for patients with operable non-small cell lung cancer in a phase 3 trial.
Read MoreThe first participant has been dosed in a Phase 3 study of Moderna’s Flu-COVID vaccine candidate (mRNA-1083) in the US, according to the company.
Read More